Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Sophie Nisse-Durgeat"'
Publikováno v:
Vascular Health and Risk Management, Vol Volume 3, Pp 165-171 (2007)
Ramzi EL Féghali1, Sophie Nisse-Durgeat2, Roland Asmar11The CardioVascular Institute, Paris, France; 2Laboratoires Takeda, Puteaux, FranceObjective: To study the effect of candesartan cilexetil (CC) in the management of blood pressure (BP) in diabet
Externí odkaz:
https://doaj.org/article/dbb4a4111caf4f5ebd83d72ca66a6d70
Publikováno v:
Vascular Health and Risk Management, Vol Volume 2, Pp 317-323 (2006)
Roland Asmar1, Sophie Nisse-Durgeat21The Cardiovascular Institute, Paris, France; 2Laboratoire Takeda, Puteaux, FranceAbstract: This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8–16 mg) in elderly (>65
Externí odkaz:
https://doaj.org/article/c003239dc7974b1aaa30a6b53443f55b
Autor:
Patrick Jourdain, Nicolas Pages, Walid Amara, Philippe Maribas, Stephane Lafitte, Herve Lemieux, Florianne Barritault, Marie-France Seronde, Jean-Philippe Labarre, Hamida Chaouky, Chloe Bedel, Laurent Betito, Sophie Nisse-Durgeat, Francois Picard
Publikováno v:
Annales de Cardiologie et d'Angéiologie. 72:101606
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::affa08772770fb711ad2e9755accbf27
https://doi.org/10.1016/j.ancard.2023.101606
https://doi.org/10.1016/j.ancard.2023.101606
Publikováno v:
Vascular Health and Risk Management, Vol 2009, Iss default, Pp 175-183 (2009)
Vascular Health and Risk Management
Vascular Health and Risk Management
JP Baguet1, R Asmar2, P Valensi3, S Nisse-Durgeat4, JM Mallion11Clinique de Cardiologie, CHU de Grenoble, Grenoble, France; 2Institut CardioVasculaire, Paris, France; 3Service d’Endocrinologie-Diabétologie-Nutrition, CHU Jean Verdier, AP-HP, Bondy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe1c6a2e06457e123642261225cc75e6
http://www.dovepress.com/effects-of-candesartan-cilexetil-on-carotid-remodeling-in-hypertensive-a2812
http://www.dovepress.com/effects-of-candesartan-cilexetil-on-carotid-remodeling-in-hypertensive-a2812
Publikováno v:
International Journal of Cardiology. 124:188-192
Context The epidemic of heart failure (HF) in France has not been fully investigated and data on both the systolic and diastolic forms are limited. Objectives To determine the prevalence, aetiology and treatments of both forms in French patients over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642422779f476f5ed6b34ff428a837ce
https://doi.org/10.1016/j.ijcard.2007.01.050
https://doi.org/10.1016/j.ijcard.2007.01.050
Publikováno v:
The British Journal of Diabetes & Vascular Disease. 7:18-24
Media Intima Thickness Evaluation of Candesartan (MITEC), a multicentre, randomised, double-blind, parallel-group study assessed the effect of candesartan cilexetil (CC) versus amlodipine (AML) administered during three years, on carotid intima-media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b286a566776f4e8f13c729a9cfe0991
https://doi.org/10.1177/14746514070070010401
https://doi.org/10.1177/14746514070070010401
Autor:
Marion Le Chapellier, Sébastien Czernichow, Jacques Blacher, Sophie Nisse-Durgeat, Michel Safar, Olivier Roux
Publikováno v:
Blood Pressure. 15:6-13
Only a minority of all hypertensives is well controlled in the population. In order to assess the proportion of well controlled hypertensives and the factors associated with hypertension control in France, we designed an observational cross-sectional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04782b16e0d2450fcfd5d88391094ae9
https://doi.org/10.1080/08037050500450114
https://doi.org/10.1080/08037050500450114
Autor:
Sophie Nisse-Durgeat, Roland Asmar
Publikováno v:
Vascular Health and Risk Management
This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8-16 mg) in elderly (65 years) hypertensive patients. Patients (n=3013) received CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e535edb1f999c11199da0202120e945b
https://pubmed.ncbi.nlm.nih.gov/17326337
https://pubmed.ncbi.nlm.nih.gov/17326337
Autor:
Sophie Nisse-Durgeat, Marie-Paule Ramée, Sonia Goineau, Danielle Pape, Pascal Guillo, Eric Bellissant
Publikováno v:
Journal of cardiovascular pharmacology. 40(2)
The effects of the selective angiotensin II type 1 receptor antagonist candesartan on cardiac, systemic, and regional hemodynamics and on cardiac, pulmonary, and hepatic histomorphometry were investigated in cardiomyopathic hamsters (CMHs), Bio TO-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7c68a911216622d59ab1d2235c26da2
https://pubmed.ncbi.nlm.nih.gov/12131548
https://pubmed.ncbi.nlm.nih.gov/12131548
Publikováno v:
Journal of Hypertension. 25:A9
To assess the effect of an ARB, candesartan cilexetil (CC), on blood pressure (BP) from 5 double-blind, randomised, studies in hypertensive patients.Similar design was used in the 5 selected studies. Following 2-4 weeks run-in period with placebo, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b77cc00be0cf8c83413134d46db5b7c
https://doi.org/10.1097/01.hjh.0000298992.09892.a6
https://doi.org/10.1097/01.hjh.0000298992.09892.a6